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Abstract 
The genetic basis of complex diseases involves alterations on multiple genes. Unravelling the 
interplay between these genetic factors is key to the discovery of new biomarkers and treatments. In 
2014, we introduced GUILDify, a web server that searches for genes associated to diseases, finds 
novel disease-genes applying various network-based prioritisation algorithms and proposes candidate 
drugs. Here, we present GUILDify v2.0, a major update and improvement of the original method, 
where we have included protein interaction data for seven species and 22 human tissues and 
incorporated the disease-gene associations from DisGeNET. To infer potential disease relationships 
associated with multi-morbidities, we introduced a novel feature for estimating the genetic and 
functional overlap of two diseases using the top-ranking genes and the associated enrichment of 
biological functions and pathways (as defined by GO and Reactome). The analysis of this overlap 
helps to identify the mechanistic role of genes and protein-protein interactions in comorbidities. 
Finally, we provided an R package, guildifyR, to facilitate programmatic access to GUILDify v2.0 
(http://sbi.upf.edu/guildify2)   
Introduction 
Complex diseases such as cancer, diabetes, neurodegenerative disorders or cardiovascular diseases 
are rarely caused by a single genetic perturbation and usually involve polygenic modifications on the 
underlying interconnected cellular network. Understanding the genetic basis of diseases and the 
interactions of disease-associated proteins in the protein interaction network (PIN) is essential for the 
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development of new rational therapeutic strategies. Despite recent large-scale genotyping efforts, 
information on disease-gene associations is still limited, often explaining a small percentage of the 
phenotypic variance observed among individuals [1]. To address this limitation and infer novel 
disease-gene associations, various disease-gene prioritisation methods have been suggested, 
exploiting the “guilt-by-association” principle over certain features of disease-genes such as similarity 
in sequence and functional annotations, clustering in the linkage interval, or proximity in the PIN [2]. 
Indeed, albeit the PINs being incomplete [3], the proximity to disease-genes in the PIN has proven 
extremely useful in prioritising disease-associated genes [4]. Consequently, a number of tools and 
web servers has been developed to expand the number of disease-associated genes using the 
interactome [5–9]. 
Previously, we presented GUILDify, a web server that applies the prioritisation algorithms 
developed in GUILD software to find novel disease-gene associations based on the connectedness of 
genes in the PIN [10,11]. GUILDify searches for genes starting from user-provided keywords such as 
the names of diseases or gene symbols in the BIANA knowledge database. It uses the genes 
associated to the keywords as seeds and the PIN for the selected organism to apply graph theory 
algorithms to prioritise new disease genes. Recently, GUILDify has been applied to: (i) find 
comorbidities across genetic diseases [12]; (ii) construct PINs specific to breast cancer metastasis to 
lung and brain [13]; (iii) identify candidate genes for body size in sheep [14] and (iv) prioritise 
preeclampsia pathogenesis [15]. 
Here, we present a comprehensive upgrade, GUILDify v2.0, where we updated the underlying 
biological databases in BIANA knowledge database (protein and drug-target interactions, functional 
and disease annotations) and: (i) facilitated the use of seven species-specific PINs and 22 human 
tissue-specific PINs; (ii) increased the quality and number of disease-gene associations by 
incorporating DisGeNET to our datasets; (iii) incorporated the option to search by drug name, allowing 
the prioritisation of genes based on known drug targets to uncover the neighbourhood of the PIN 
affected by the drug; (iv) improved the visualisation of the results using cytoscape.js; (v) refined the 
definition of top-ranking genes based on whether they had similar functional annotations as the 
seeds,  thus providing the biologically most coherent subnetwork relevant to a given disease; (vi) 
introduced a feature to measure the genetic and functional overlap of the top-ranking genes of two 
different diseases, supporting the investigation of disease comorbidities; (vii) implemented a new drug 
repurposing functionality to propose novel indications for a given drug based on the genetic and 
functional overlap; and (viii) developed an R package to facilitate the programmatic access to the 
methods implemented in the web server. 
Results and Discussion 
Advances 
1. Identifying genetic and functional similarities across diseases 
In recent works, we have shown that the genetic and functional similarities of diseases in the PIN can 
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be used to characterise co- and multi-morbidities across diseases [12] and also to repurpose existing 
drugs targeting these diseases [16]. Motivated by these findings and to provide systematic insights on 
disease-disease relationships, GUILDify v2.0 now allows users to identify the overlap between two 
previously submitted results, i.e. sets of genes linked to two different diseases. Accordingly, given two 
job IDs corresponding to the prioritisation results of two different diseases, GUILDify v2.0 provides: (i) 
the overlap between the top-ranking genes of the two diseases; (ii) the overlap between the enriched 
functions among the top-ranking genes of the two diseases; (iii) the enriched functions among the 
common top-ranking genes; and (iv) a network visualisation of the interactions between common top-
ranking genes. Moreover, GUILDify v2.0 also calculates the Fisher’s exact test to quantify the 
significance of the overlap between genes and functions and report one-sided P-value (see details in 
Supplementary Material). GUILDify v2.0 is the first server that permits the use of gene prioritisation 
results to explore disease-disease relationships with such simplicity and flexibility.  
2. Prioritisation of drug targets 
GUILDify v2.0 now allows to search by a drug in addition to a phenotype and returns a list of drug-
target associations integrated from DrugBank [17], DGIdb [18], DrugCentral [19] and ChEMBL [20] 
(see details in Supplementary Material). This new functionality allows the characterisation of the 
neighbourhood of the drug in the PIN, i.e. neighbouring proteins to those targeted by the drug, and 
thus providing insights on the potential mechanism of action of the drug. Moreover, the novel feature 
of assessing the overlap between two network expansion runs (i.e. two job IDs) can also be applied in 
multiple scenarios to: (i) identify the similarity between the neighbourhood of two drugs in the PIN, 
which can be useful to identify drug interactions; (ii) compare the neighbourhood of a disease with the 
neighbourhood of a drug in the PIN, which can be applied to drug repurposing. Such novel features 
make GUILDify v2.0 one of the most easy-to-use and flexible web servers to inspect the effect of 
drugs in the PIN. 
3. Screening diseases to identify potential new indications of known drugs 
Building upon new technical developments mentioned above, GUILDify v2.0 now offers a novel drug 
repurposing functionality. Given a job ID associated with a drug (or a list of drug targets), this feature 
automatically calculates the overlap of genes (or functions) between the given drug and a set of pre-
calculated diseases. Details on the method and validation of drug repurposing are described in detail 
at Supplementary Material. 
4. Tissue and species-specific PINs 
The analysis of the protein interactions in a tissue-specific context is becoming increasingly relevant 
to understand genetic diseases and find improved treatments [21]. We have included tissue-specific 
networks derived from 22 different human tissues (see Supplementary Table S1). To create these 
networks, we filtered the interactions in the global PIN using RNAseq data from GTEx [22], keeping 
only the interactions between proteins encoded by genes that are expressed in a given tissue (i.e. 
considering only transcripts with TPM (transcripts per kilobase million) expression values of 1 or 
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higher (see details in Supplementary Material). We have also included 7 species-specific PINs 
derived from experimentally determined protein-protein interactions. Although the coverage of 
interactomic data for some species is low (e.g., 11,943 interactions in rat vs 320,337 interactions in 
human), these PINs provide a reliable backbone for interactome-based analyses (e.g., in preclinical 
research) as opposed to PINs generated by predicted interactions based on homology information. 
5. Disease-gene information from DisGeNET 
We incorporated DisGeNET, one of the largest repositories of genes and variants associated to 
human diseases [23]. DisGeNET relies on data from UniProt [24], CTD [25], CLINVAR [26], 
ORPHANET [27], GWAS Catalog [28], PsyGeNET [29] and HPO [30] and is integrated in BIANA [31]. 
To investigate the increase in the number of disease-gene associations between versions 1 and 2 of 
GUILDify, we checked the number of associations for the lowest-level non-obsolete diseases from 
Disease Ontology [32] that were available in our repositories (2,190 terms). GUILDify v1 contains 
gene associations for 1,505 diseases and 4,171 genes (2.8 genes per disease), while updated 
GUILDify v2.0 has gene associations for 2,064 diseases and 11,615 genes (5.6 genes per disease on 
average).  
6. Functional-coherency based selection of top-ranking genes 
One of the main issues when working with disease-gene prioritisation is to select the most relevant 
(top ranked) genes associated with a given disease. The user can select top 1% or 2% highest 
scoring genes among all the proteins in the PIN as top ranked genes. In GUILDify v2.0, we also 
introduced a cutoff based on the functional validation approach described in Ghiassian et al. [5] and 
provided a new panel visualising the significance of the functional enrichment (P-value) as a function 
of the number of top-ranking genes included in the validation (implemented in Plotly). In brief, the 
highest-scoring non-seed proteins are iteratively included in the top-ranking set, provided that they 
maintain the functional coherency of the existing top-ranking set (see details in Supplementary 
Material). Note that this approach might be too restrictive for some complex diseases in which the 
information on known disease-gene associations is limited, failing to represent the functional diversity 
involved in the disease. 
7. Visualisation of the top-ranking subnetwork 
GUILDify v2.0 uses the JavaScript-based network visualisation library, Cytoscape.js [33], to show the 
subnetwork of the top-ranking proteins and the drugs targeting these proteins. The user can decide 
the cutoff to define the top ranked proteins to be visualised (top 1%, top 2% or functionally-coherent 
as mentioned above). In addition to seeds (green hexagons), top-ranking proteins (yellow circles) and 
drugs (blue diamonds), the subnetwork includes the proteins that connect the seeds to the largest 
connected component induced by seeds (named “linkers” and shown as grey circles, see details in 
Supplementary Material).  
8. R package 
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We have included an R package in order to provide programmatic access to GUILDify v2.0 through R 
statistical computing environment (https://www.r-project.org/). The package implements methods to 
query and retrieve results from the web server as an R data frame, allowing users to run multiple 
queries for more high-throughput and/or systematic analyses. The package and documentation are 
available online at: http://sbi.upf.edu/guildify2. 
GUILDify v2.0 workflow 
1. Input 
The interface of GUILDify v2.0 is designed to be simple and intuitive. The input varies slightly 
depending on the desired task: (i) a new search; (ii) retrieving results from a previous run; and (iii) 
calculating genetic and functional overlap between two previous runs. For a new search, we require 
two steps: first the selection of seeds (genes associated with a phenotype or drug) and second the 
selection of parameters to run the prioritisation algorithms. For the selection of seeds the user has to 
provide: (i) either keyword(s) describing the phenotype/drug of interest or a set of specific gene 
names separated by a semicolon; (ii) the species of interest (default value: Homo sapiens); (iii) the 
tissue of interest (default value: All); and (iv) the PIN source (default value: BIANA). If the user 
provides a keyword (or set of keywords) describing a phenotype or drug, the server searches genes 
containing the keyword in BIANA knowledge database (i.e. integrating information from many 
resources), otherwise it uses the list of provided gene names. The server shows the selected seeds, 
which can still be filtered and selected by the user. Then, for the prioritisation parameters the user can 
select to run the “disease module detection algorithm” (DIAMOnD, downloaded from 
https://github.com/dinaghiassian/DIAMOnD) [5] or to use one of the several prioritisation algorithms 
from the GUILD package (default value: NetScore with default parameters). Finally, to retrieve results, 
the required input is the job ID of a previous run, while for calculating genetic and functional overlap 
the inputs are two job IDs of previous runs. 
2. Output 
GUILDify v2.0 outputs the ranking of the nodes in the PIN and the visualisation of the subnetwork 
involving the top-ranking genes in a cytoscape.js panel. In addition, the output page has: (i) a panel 
showing the P-values of functional enrichment of the ranked nodes; (ii) two panels with functions 
enriched among the top-ranking nodes and seeds, respectively; and (iii) one panel with the drugs that 
target the top-ranking proteins. 
For the “Overlap between two results” option, the server provides: (i) the list of the common top-
ranking genes and the significance of the overlap assessed by a Fisher’s exact test (see details in 
Supplementary Material); (ii) the network visualisation of the common top-ranking genes including the 
“linkers” (see above); (iii) the list of enriched functions of the common genes; iv) the list of common 
enriched functions of both results and the significance of the overlap; and v) the drugs targeting the 
proteins of the common PIN. Using this functionality, the users can identify the overlap between any 
two queries such as between two diseases, two drugs or a disease and a drug. Although we do not 
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provide the overlap between interactions of top-ranking proteins in a separate table, these interactions 
can be investigated in the network visualisation panel.  
Case studies 
1. Exploring the mechanistic links between rheumatoid arthritis and asthma 
In multiple studies, rheumatoid arthritis and asthma are linked as a potential comorbidity, although the 
mechanisms underlying this association remain unclear [34]. Using the new functionality of GUILDify 
v2.0, we can assess the overlap between diseases and thus propose a potential mechanism to 
explain the association between them. Querying for “rheumatoid arthritis” and “asthma” returns 156 
and 96 seeds, respectively coming from DisGeNET, OMIM, and UniProt. There are already 12 seeds 
in common (Fisher’s exact test, one-sided P-value = 1.4·10-9) and 18 common functions out of the 
total enriched functions of the seeds (P-value = 9.3·10-23).   After running GUILDify v2.0, we select 
290 and 181 top ranked genes using functional-coherency based cutoff for rheumatoid arthritis and 
asthma, respectively. We find that the number of common genes increases to 55 (yielding a P-value = 
5.9·10-48), while the number of common functions (biological processes) increases to 31 (P-value = 
8.1·10-46). The link between these diseases is significant even when the seeds are removed from the 
top-ranking genes (see Supplementary Material). Among the shared top-ranking genes, we find 
Tumor Necrosis Factor (TNF), which has been proposed as a potential drug target for asthma and 
rheumatoid arthritis, and highlighted as a potential precursor of the comorbidity [12]. We also find 
HLA-DRB1 and several interleukins (IL18, IL1B, IL3), taking part of the immune response potentially 
involved in both diseases. Furthermore, the most common enriched functions relate to inflammatory 
processes such as “inflammatory response”, “positive regulation of interferon-gamma production” and 
“positive regulation of T-helper 1 cell cytokine production”. These functions appear again if we check 
the functions enriched by the common genes, along with other functions such as “T-helper 1 type 
immune response” or “negative regulation of type 2 immune response”, highlighting the involvement 
of type 1 immune response in both diseases. As negative controls, we repeated the analysis using 
other disease pairs that are not likely to be comorbid such as “rheumatoid arthritis” - “breast cancer” 
and “asthma” - “breast cancer”, finding drastically reduced number of genes in the overlap between 
these disease pairs (see Supplementary Material). The results can be further explored in Figure 1 and 
in the pre-calculated examples section of the web. Additionally, we compared the functional relevance 
of the top-ranking genes identified by NetScore with DIAMOnD, based on the analysis in Sharma et 
al. [35] (see Supplementary Material). We checked the enrichment of top-ranking genes among the 
pathways containing the seed genes of asthma and rheumatoid arthritis, showing that both methods 
significantly recover the pathways in each disease. Furthermore, NetScore identified more genes that 
belonged to the pathways shared between asthma and rheumatoid arthritis compared to DIAMOnD. 
2. Study of the mechanism of non-small cell lung carcinoma drugs 
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Typically induced by 
exposure to toxic substances, the NSCLC pathology has been specially associated with a mutation in 
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the Epidermal Growth Factor Receptor (EGFR) [36]. In a recent study, 9 drugs were proposed to treat 
this disease [37], 6 of them having drug-target interactions reported: Afatinib, Ceritinib, Crizotinib, 
Erlotinib, Gefitinib and Palbociclib. Given that we can now identify potentially new relationships 
between drugs and diseases using drugs as queries, we investigate whether the neighbourhood of 
the targets of these drugs in the PIN significantly overlaps with the neighbourhood of the genes 
associated with NSCLC. We used GUILDify v2.0 to define this neighbourhood. We observe that the 
genetic overlap is always significant, except for one of the drugs (Palbociclib, see Table 1).  
   We confirm the significance by applying the same approach to breast cancer, showing that Ceritinib, 
Crizotinib and Palbociclib produce a significant genetic overlap, although the number of common 
genes in each case is substantially lower than it is in NSCLC (see Table 1). These results are 
consistent with the fact that Palbociclib is primarily indicated for breast cancer and it has been 
recently repurposed for NSCLC [38]. The small but significant overlap of Ceritinib and Crizotinib 
suggests that these two drugs might also be considered as potential repurposing candidates. We note 
that using the top-ranking nodes increases the significance of the genetic overlap (with lower P-
values) compared to the overlap using only seeds (genes associated with a pathophenotype and 
direct targets of drugs). The significant overlap between the top ranked genes identified using these 
drugs and the top ranked genes for NSCLC (but not for the top ranked genes for breast cancer) 
suggests that GUILDify v2.0 can help understanding how drugs exert their action on certain diseases. 
Indeed, the characterisation of the neighbourhood in the PIN that is affected by drugs opens a wide 
range of possibilities for drug repurposing research. 
 
Methods 
Datasets 
GUILDify v2.0 uses BIANA [31] for the integration of biological interaction databases with information 
on drugs, genes, proteins, functions, pathways and diseases. To create the tissue-specific PINs, we 
use the RNAseq data from GTEx V7 [22]. Phenotype-gene associations are extracted from 
DisGeNET, OMIM, Uniprot, and Gene Ontology. Drug-target associations are taken from DrugBank 
[17], DGIdb [18], DrugCentral [19] and ChEMBL [20]. See Supplementary Material for details on the 
datasets.  
Prioritisation algorithms 
GUILDify v2.0 uses four different network-based prioritisation algorithms: NetShort, NetZcore, 
NetScore and DIAMOnD. For details on these algorithms see references [5,10,11] and the 
Supplementary Material.  
Overlap and functional enrichment analysis 
We use one-sided Fisher’s exact test to calculate the overlap between two sets of genes or functions 
and use Benjamini-Hochberg multiple hypothesis testing procedure (where applicable). The functions 
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enriched among seeds and top-ranking nodes as well as common functions between two diseases 
are calculated as explained in a previous work [12] (see details in Supplementary Material).  
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TABLE AND FIGURES LEGENDS 
 
Figure 1. GUILDify v2.0 example study on the comorbidity between asthma and rheumatoid arthritis. 
First, we run the prioritisations of the two diseases by searching (1) and selecting (2) the genes. After 
obtaining the ranking of proteins from the prioritisation (3), we use both job IDs to check their overlap 
(4) and inspect the genetic and functional relationships between them (see details at 
http://sbi.upf.edu/guildify2 in the pre-calculated examples section. 
Table 1. Results of the genetic and functional overlap between the subnetwork of genes associated 
with “non small cell lung carcinoma” and “breast cancer” (top ranking genes and seeds) and the 
subnetwork of genes associated with the targets of drugs Afatinib, Ceritinib, Crizotinib, Erlotinib, 
Gefitinib and Palbociclib (drug targets and top-ranking genes obtained with GUILDify v2.0). P-values 
shown have been corrected using the Benjamini-Hochberg correction for multiple tests. Results with 
non-significant P-value are highlighted in red. 
